Paul Tanico, Chief Strategy Officer, Synaps DX, shares insights in McKnight's Senior Living on the transformative power of holistic #dementia care, reducing staff burdens and enhancing market position. Learn more: https://t.co/SK7wOilwjj #DementiaCare#SeniorLiving#alzheimers
SYNAPS Dx is proud to introduce its new Scientific Advisory Board of esteemed experts to drive innovation in Alzheimer’s Disease diagnostics, including SDx’s DISCERN™ test, the only autopsy-validated Alzheimer's test. Learn more: https://t.co/IwOtOJ6cKo #Innovation#Healthcare
SDx CEO, Frank Amato, spoke with @AlzSpksRadio discussing early diagnosis of #Alzheimers disease during National Alzheimer’s Disease Awareness Month and National Family #Caregivers Month. Listen to the interview wherever you get your podcasts: https://t.co/ZzRRdk2lco
We are pleased to share that SDx CEO, Frank Amato was recently featured in @TodaysGeriMed to discuss the importance of accurate #Alzheimer’s #diagnosis for ensuring proper prescribing and #treatment. Learn more in the timely article here: https://t.co/wYnvjppJXT
During National Alzheimer’s Disease Awareness and National Family Caregiver Months, SDx supports those impacted by #Alzheimers disease and shows appreciation for those who provide care to family members with #Alzheimersdisease. Learn more about our mission https://t.co/WVK6r3O9F9
SDx is proud to observe November as National Alzheimer’s Disease Awareness and National Family #Caregivers Months. Join us in appreciating caregivers who tirelessly support family and friends who are impacted by #Alzheimers: https://t.co/3zCW3SpsAq
We are excited to announce SDx CEO, Frank Amato's appearance on @AmericanBrainCo podcast, Voices for the Brain. He shares the importance of an early and accurate #Alzheimers disease diagnosis and how the DISCERN test can inform patients: https://t.co/nEL1WzeOBS
CMS' newest care coordination enhancement model, GUIDE, aims to enhance care for Medicare beneficiaries with #dementia. Physicians can help identify patients with cognitive decline or #Alzheimers to see who qualifies for GUIDE with annual wellness visits: https://t.co/0BwHPSbwNp
SDx CEO and President, Frank Amato, was recently featured on the Fading Memories Podcast to explain DISCERN and its revolutionary impact on the #Alzheimers disease community. Listen to the full episode here: https://t.co/raMq08cbzf
As World Alzheimer’s Month and Healthy Aging Month come to a close, we reflect on the importance of an early and accurate #Alzheimers disease (AD) diagnosis. AD risk factor education and prevention is crucial in taking proactive measures to ensure healthy #cognitive aging.
SDx is proud to announce the newest feature of CEO and President, Frank Amato, in Alternative Medicine Magazine to close out September as World #Alzheimers Month and share insights on AD risk factors and lifestyle changes for healthy cognitive aging: https://t.co/NHkRK1l89R
As we observe World Alzheimer’s Month and Healthy Aging Month, this year’s theme of “Never too early, never too late” points to the importance of recognizing potential Alzheimer's disease risk factors and raises awareness for risk education: https://t.co/3PnjlrHDPH
SDx is proud to announce a new article from CEO and President, Frank Amato, in Pharmacy Times to share his insights on the value and challenges of obtaining an accurate AD diagnosis in Alzheimer's disease: https://t.co/jYXHUEFjZm
SDx presented at BRAINWeek2023 to share the MI assay identified Alzheimer's in people diagnosed with dementia, even in the presence of mixed dementia and physician feedback showing they were 4x as likely to prescribe AD drugs with a positive DISCERN test: https://t.co/3TFvLeqysH
September is World Alzheimer’s Month and Healthy Aging Month! Join us in this observance to raise awareness for Alzheimer’s disease risk factor prevention and education. Our most recent blog post emphasizes the need for an early, accurate AD diagnosis: https://t.co/D384O6UVTi
SDx is pleased to announce our participation at BRAINWeek 2023. We will deliver a presentation on “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer's Disease Even in the Presence of Co-Morbid Pathologies”, and poster at booth #119: https://t.co/ElA9F5zWq2
We are excited to share our recent blog following SDx CEO, Frank Amato's interview with @writeformeio! Amato articulates the value of DISCERN and provides insights on how the test can provide physicians with a confident #Alzheimers disease diagnosis: https://t.co/MfGrkOheDY